Login
Products
Login
Home
Alerts
Search
Watchlist
Products

EID Parry (India) Ltd

EIDPARRY
NSE
837.20
0.96%
Last Updated:
29 Apr '26, 4:00 PM
Company Overview
Guidance Tracker
Alert
Watchlist
Note

EID Parry (India) Ltd

EIDPARRY
NSE
837.20
0.96%
29 Apr '26, 4:00 PM
Company Overview
Guidance Tracker
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
14,892Cr
Close
Close Price
837.20
Industry
Industry
Sugar
PE
Price To Earnings
12.51
PS
Price To Sales
0.40
Revenue
Revenue
37,475Cr
Rev Gr TTM
Revenue Growth TTM
23.46%
PAT Gr TTM
PAT Growth TTM
44.50%
Peer Comparison
How does EIDPARRY stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
EIDPARRY
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
6,8607,0269,0597,7705,5576,7479,3308,7206,8118,72411,62410,316
Growth YoY
Revenue Growth YoY%
21.1-1.7-20.0-21.6-19.0-4.03.012.222.629.324.618.3
Expenses
ExpensesCr
6,2176,3598,0027,3495,0886,2638,3598,0186,2817,91810,4279,481
Operating Profit
Operating ProfitCr
6446681,0574214694839727025308051,198835
OPM
OPM%
9.49.511.75.48.47.210.48.17.89.210.38.1
Other Income
Other IncomeCr
-23-151473211345561094439015160
Interest Expense
Interest ExpenseCr
878274538684949996104129103
Depreciation
DepreciationCr
10594101112113117123130142176158204
PBT
PBTCr
4284771,0292883823278115827356151,062588
Tax
TaxCr
1411522477188102219166195151296151
PAT
PATCr
287325782217294226592416539464766437
Growth YoY
PAT Growth YoY%
-33.1-34.338.4-55.02.6-30.5-24.391.983.3105.629.55.2
NPM
NPM%
4.24.68.62.85.33.46.34.87.95.36.64.2
EPS
EPS
10.16.125.56.712.45.117.211.016.113.823.913.1

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
13,95315,35814,39115,37316,55617,12918,55623,52135,24429,41331,60937,475
Growth
Revenue Growth%
10.1-6.36.87.73.58.326.849.8-16.57.518.6
Expenses
ExpensesCr
12,94114,51712,96514,06815,11015,24116,46721,14632,05026,79828,92134,107
Operating Profit
Operating ProfitCr
1,0128411,4261,3051,4451,8882,0892,3753,1942,6162,6873,368
OPM
OPM%
7.35.59.98.58.711.011.310.19.18.98.59.0
Other Income
Other IncomeCr
108179159150891281724045276652743
Interest Expense
Interest ExpenseCr
420451417336425430236152298295372432
Depreciation
DepreciationCr
244250248251272319332334376421512679
PBT
PBTCr
4553199208688371,2661,5392,1292,5642,1752,4553,000
Tax
TaxCr
179144211351399377540555737558682793
PAT
PATCr
2761757085174388891,0001,5741,8281,6181,7732,207
Growth
PAT Growth%
-36.6304.2-26.9-15.4103.112.557.416.1-11.59.624.5
NPM
NPM%
2.01.14.93.42.65.25.46.75.25.55.65.9
EPS
EPS
6.61.929.414.58.726.425.351.253.450.749.566.9

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
181818181818181818181818
Reserves
ReservesCr
2,2092,3702,7332,9523,1103,5024,5655,3086,0677,0557,9388,628
Current Liabilities
Current LiabilitiesCr
8,3779,4778,5169,79010,9128,5905,7457,1088,4719,30010,39514,196
Non Current Liabilities
Non Current LiabilitiesCr
1,3991,2621,0285726251,2086907357699811,0551,265
Total Liabilities
Total LiabilitiesCr
12,89914,16613,43114,59915,99015,02413,26415,94318,77821,49324,38129,958
Current Assets
Current AssetsCr
8,7389,9509,46010,67212,00310,4488,87310,83912,59315,18716,31919,904
Non Current Assets
Non Current AssetsCr
4,1614,2163,9723,9273,9874,5764,3905,1036,1856,3068,06310,055
Total Assets
Total AssetsCr
12,89914,16613,43114,59915,99015,02413,26415,94318,77821,49324,38129,958

Cash Flow

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
2224371,969259-521,9864,7712,2783591,9741,936
Investing Cash Flow
Investing Cash FlowCr
-307-190-14813-358-292-560-1,733486-1,740-2,782
Financing Cash Flow
Financing Cash FlowCr
-142-221-1,8424234-1,769-3,598-499-184-49774
Net Cash Flow
Net Cash FlowCr
-22826-21314-376-7561346660-263-772
Free Cash Flow
Free Cash FlowCr
352331,83982-3961,6284,4551,845-3701,0511,323
CFO To PAT
CFO To PAT%
80.2249.4278.050.1-12.0223.4477.2144.819.6122.0109.2
CFO To EBITDA
CFO To EBITDA%
21.952.0138.119.9-3.6105.2228.395.911.275.572.1

Ratios

Consolidated
Standalone
Financial YearMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
3,0933,8344,9864,8933,6432,4745,6448,0188,2969,68613,962
Price To Earnings
Price To Earnings
30.7111.39.619.123.75.312.68.88.810.815.9
Price To Sales
Price To Sales
0.20.30.30.30.20.10.30.30.20.30.4
Price To Book
Price To Book
1.41.61.81.61.20.71.21.51.41.41.8
EV To EBITDA
EV To EBITDA
7.09.75.96.35.73.52.93.12.63.24.8
Profitability Ratios
Profitability Ratios
GPM
GPM%
25.023.028.727.327.829.028.725.120.823.023.2
OPM
OPM%
7.35.59.98.58.711.011.310.19.18.98.5
NPM
NPM%
2.01.14.93.42.65.25.46.75.25.55.6
ROCE
ROCE%
13.211.020.817.215.721.930.534.637.228.026.5
ROE
ROE%
12.47.325.817.414.025.321.829.630.022.922.3
ROA
ROA%
2.11.25.33.52.75.97.59.99.77.57.3
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Executive Summary** EID Parry (India) Ltd, a member of the Murugappa Group, is undergoing a strategic transformation from a traditional sugar-focused manufacturer into a diversified **Food, Nutrition, and Bioenergy enterprise**. With a 235-year legacy and operations rooted in South India, the company is leveraging its trusted **Parry’s brand**, integrated manufacturing infrastructure, and deep agrarian engagement to expand into high-growth FMCG segments, particularly **value-added sweeteners, staples (rice, dals, millets)**, and globally competitive **nutraceuticals**. This pivot is designed to reduce vulnerability to commodity sugar cycles, regulatory risks, and climate volatility while capturing a larger share of Indian households’ grocery baskets through branded, healthy, and convenient food offerings. --- ### **Core Business Segments & Strategic Shift** #### **1. Sugar & Bioenergy (Established Verticals)** Despite diversification, sugar remains the core revenue generator, supported by integrated bioenergy operations: - **Sugar Operations** - Operates **six sugar factories** across Tamil Nadu, Andhra Pradesh, and Karnataka with a combined **cane crushing capacity of 40,800 TCD**. - Market leader in **packaged sugar in South India** under the ‘Parrys’ brand. - Supplies **pharma-grade, bulk, and B2B sugar** to global F&B, pharmaceutical, and confectionery companies (e.g., Coca-Cola, Dr. Reddy’s). - Over 60% of sugar sales now come from **branded retail and institutional channels**, reducing reliance on open-market prices. - **Bioenergy & Distillery** - **Ethanol production capacity: 582 KLPD**, among the highest in South India. - Strategically expanding under the **Ethanol Blending Programme (EBP)** with new plants in Haliyal (120 KLPD) and Nellikuppam (45 KLPD). - Capable of **multi-feed distillation**—using molasses, juice, or grain—offering flexibility during supply fluctuations. - Generates **140 MW of surplus green power** via bagasse co-generation, contributing to energy self-sufficiency and carbon neutrality goals. --- #### **2. Consumer Product Group (CPG) – Growth Engine** Launched in FY2023–24 (rebranded as “Parry 2.0”), the CPG represents a **strategic pivot toward FMCG** and consumer-centric innovation. - **Product Portfolio** - **Sweeteners**: Parry’s Amrit Gold, Amrit Brown Sugar, Jaggery, and SweetCare Low-GI Sugar (GI < 55). - **Staples**: 15+ rice varieties, 5 millets, and 4 dals under **Parry’s Consumer Products**, targeting healthy and urban lifestyles. - **Total SKUs**: Over **55 SKUs** across sweeteners, rice, dals, and millets. - **Market Performance (as of Aug 2025)** - **Non-Sweetener Sales**: Achieved **8,569 MT in Q1 FY26**, a **40% YoY volume increase** (up from 6,140 MT in Q1 FY25). - **Non-Sweetener Revenue**: Reached **INR 291 crore in first-year sales** (FY24–25), validating early market traction. - **Volume Growth in Staples**: H1 FY25 sales reached **82,240 MT**, up **21% YoY**, with realization improving to **₹40.19/kg**. - **Growth Strategy** - **Asset-light model**: Outsourcing production and co-packing to scale rapidly with low capital intensity. - **Distribution**: Over **200,000 retail outlets** in South India (doubled from 110,000 in FY23). Target: **500,000 across India**. - **Channels**: Kirana stores, modern trade, e-commerce, and HORECA expansion in metro and Tier 1/2 cities. - **Marketing**: 360-degree campaigns using TV, digital, influencers, and celebrity endorsements for brand visibility. --- #### **3. Nutraceuticals – Global Premium Segment** A high-margin, export-oriented business with leadership in organic microalgae-based wellness. - **Key Offerings**: - **Organic Spirulina**: Globally recognized as premium, high-phycocyanin (>17%) product. - **Organic Chlorella**: High chlorophyll (2–2.5%), scientifically validated for B12 bioavailability. - **Saw Palmetto Extracts (Flomentum®)**: USP-verified B2C brand for prostate health, distributed in the USA via wholly-owned subsidiary **US Nutraceuticals Inc. (Valensa)**. - **Manufacturing & Innovation** - Plants in **Oonaiyur (TN)** and **Chile** (Haematococcus for Astaxanthin). - **No sterilization policy** preserves nutrients; uses **zero/minimal excipients** in formulations. - Engaged in clinical research: dermatology applications for Saw Palmetto, B12 absorption in Chlorella. - **Global Presence** - Strong in **North America, EU, and Japan**, with products meeting **USP, FSSC 22000, Bonsucro, Organic (NOP, EU), and SMETA** standards. - Aims to reclaim leadership in **European dietary supplements**, differentiating on **quality and scientific validation** vs. low-cost Chinese alternatives. --- ### **Strategic Initiatives & Capabilities** #### **1. Diversification & Revenue Resilience** - **Revenue mix shift**: Non-sugar revenue (CPG, ethanol, nutraceuticals, co-gen) now a growing contributor. - CPG revenue surged to **₹883.89 crore in FY24** from ₹535.26 crore, while sugar revenue declined. - Goal: Reduce direct exposure to **commodity sugar markets to <10%** of total revenue. #### **2. R&D & Innovation** - **Cane R&D**: India’s only private sugar company with **in-house sugarcane breeding program**. Over **12 high-yield, disease-resistant** varieties developed via tissue culture. - **New Product Development**: - **Nucane™ Technology** (with Nutrition Innovation, Singapore): Naturally low-GI sugar using cane polyphenols. - **Ready-to-cook health mixes**, millet idly/dosa batters, and fortified staples in pipeline. #### **3. Sustainability & Circular Economy** - **Zero Liquid Discharge (ZLD)**: Nellikuppam distillery operates with 100% ZLD. - **Waste-to-Value**: - **Green Grow Media (GGM)**: Soil-less grow medium from **bagasse**, export-ready, with 400% 30-year volume growth potential. - **Bioplastics**: Under development—mulching sheets, poly bags from bagasse. - **Mineralised salt licks and cattle fodder blocks** from waste. #### **4. Digital & Precision Agriculture** - **i-Cane Management System (iCMS)**: Mobile app for real-time farm monitoring, yield mapping, and irrigation control. - **Autonomous irrigation, drone spraying, GPS yield tracking**, and AI-backed harvest scheduling improve efficiency and recovery rates. - Farmer engagement with **100,000+ sugarcane farmers** across 200,000 acres; payments within **7–12 days** of delivery. --- ### **Subsidiaries & Group Synergies** - **Coromandel International Ltd**: Farm inputs business (fertilizers, biopesticides like Azadirachtin). - **Parry Sugars Refinery India Pvt Ltd**: World-class refinery at Kakinada, exporting containerized sugar. - **US Nutraceuticals Inc. (Valensa)**: Fully owned US subsidiary, key to global nutraceutical growth. - **Algavista Greentech Pvt Ltd (JV)**: Developed **Phycocyanin** (natural blue colorant), though pricing pressures from China have challenged commercial viability. --- ### **Key Risks & Mitigation** | **Risk** | **Mitigation Strategy** | |--------|------------------------| | Sugar price volatility & policy changes | Diversify into higher-margin, non-regulated businesses | | Climate & monsoon dependency | Precision farming, drought-resistant cane varieties, regional crop diversification | | Supply chain for staples | 55 SKUs sourced from 13 suppliers across 6 states; multi-sourcing strategy | | Nutraceutical pricing pressure (esp. from China) | Focus on quality, scientific validation, and premium positioning | ---